Cargando…

Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”?

In recent years, there has been a critical change in treatment paradigms in inflammatory bowel diseases (IBD) triggered by the arrival of new effective treatments aiming to prevent disease progression, bowel damage and disability. The insufficiency of symptomatic disease control and the well-known d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonczi, Lorant, Bessissow, Talat, Lakatos, Peter Laszlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848014/ https://www.ncbi.nlm.nih.gov/pubmed/31749591 http://dx.doi.org/10.3748/wjg.v25.i41.6172

Ejemplares similares

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
por: Albader, Farah, et al.
Publicado: (2021)

Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?
por: Strohl, Matthew, et al.
Publicado: (2018)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
por: Al Khoury, Alex, et al.
Publicado: (2021)

Objective Disease Monitoring Strategies from a Tertiary Inflammatory Bowel Disease Center in Hungary
por: Lontai, Livia, et al.
Publicado: (2023)

Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease center: Access, resource utilization and outcomes
por: Nene, Sofia, et al.
Publicado: (2020)

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996–2015
por: Golovics, Petra Anna, et al.
Publicado: (2022)

The Optimal Management of Inflammatory Bowel Disease in Patients with Cancer
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2019)

Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Time Trends of Environmental and Socioeconomic Risk Factors in Patients with Inflammatory Bowel Disease over 40 Years: A Population-Based Inception Cohort 1977–2020
por: Wetwittayakhlang, Panu, et al.
Publicado: (2023)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Management of inflammatory bowel disease with Clostridium difficile infection
por: D’Aoust, Julie, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease Increases Cardiovascular Risk in Inflammatory Bowel Diseases
por: Kablawi, Dana, et al.
Publicado: (2023)

Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
por: Alrajhi, Saad, et al.
Publicado: (2020)

Maladaptive coping, low self-efficacy and disease activity are associated with poorer patient-reported outcomes in inflammatory bowel disease
por: Chao, Che-Yung, et al.
Publicado: (2019)

Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease
por: Restellini, Sophie, et al.
Publicado: (2017)

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Transition care in inflammatory bowel disease: A needs assessment survey of Quebec gastroenterologists and allied nurses
por: Strohl, Matthew, et al.
Publicado: (2017)

Inflammatory Bowel Disease and Patients With Mental Disorders: What Do We Know?
por: Fousekis, Fotios S., et al.
Publicado: (2021)

Iron Deficiency Anemia in Inflammatory Bowel Disease: What Do We Know?
por: Resál, Tamás, et al.
Publicado: (2021)

Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
por: Hart, Lara, et al.
Publicado: (2020)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Do We Mean What We Say?
por: Towner, Ausburn
Publicado: (1885)

Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
por: Chao, Che-Yung, et al.
Publicado: (2016)

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Advances in the Diagnosis and Management of Inflammatory Bowel Disease: Challenges and Uncertainties
por: Mosli, Mahmoud, et al.
Publicado: (2014)

Tight glycemic control: what do we really know, and what should we expect?
por: Nasraway, Stanley A, et al.
Publicado: (2010)

A180 CLINICAL OUTCOMES OF COVID-19 AND IMPACT ON DISEASE COURSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Wetwittayakhlang, P, et al.
Publicado: (2022)

A191 NONALCOHOLIC FATTY LIVER DISEASE AND LIVER FIBROSIS INCREASE CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kablawi, D, et al.
Publicado: (2023)

Incidence and Paris Classification of Pediatric Inflammatory Bowel Disease
por: Eszter Müller, Katalin, et al.
Publicado: (2014)

Isolated Small Bowel Amyloidosis
por: Ghaith, Jenan, et al.
Publicado: (2021)

Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2020)

Mean Age of First Sex: Do They Know What We Mean?
por: de Irala, Jokin, et al.
Publicado: (2011)

Corrigendum to “Incidence and Paris Classification of Pediatric Inflammatory Bowel Disease”
por: Müller, Katalin Eszter, et al.
Publicado: (2015)

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
por: Hasenoehrl, Carina, et al.
Publicado: (2017)

Adenocarcinoma Within Carpet-Like Pseudopolyposis
por: Xiao, Yasi, et al.
Publicado: (2020)

Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules
por: Verdon, Christine, et al.
Publicado: (2019)

What do we talk about when we talk about rhythm?
por: Obleser, Jonas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6tql4b1eu2q5obee6avuj4b37t